Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 10Active not recruiting 8Withdrawn 4Terminated 3Suspended 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 1Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 9Vincristine 6Specimen Handling 6Prednisone 6Rituximab 5Doxorubicin 5Magnetic Resonance Spectroscopy 4zanubrutinib 3prednylidene 3fludarabine 3deltacortene 3Biopsy 3tazemetostat 2fludarabine phosphate 2Radiotherapy, Intensity-Modulated 2Melphalan 2Etoposide 2Drug Therapy 2CT-P10 2Azacitidine 2Antibodies, Monoclonal 2vactosertib 1tisagenlecleucel 1sargramostim 1pembrolizumab 1obinutuzumab 1mogamulizumab 1glucarpidase 1duvelisib 1brincidofovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × tazemetostat × Lymphoid × Clear all
NCT06824701 2026-04-06

TARZAN

University of Utah

Phase 1 Suspended
24 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT06575686 2026-01-21

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

City of Hope Medical Center

Phase 2 Suspended
33 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡